Amaia Esquisabel

Amaia Esquisabel

Auto-generated profile, based on publicly available information

Amaia Esquisabel

Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country (UPV-EHU), Vitoria-Gasteiz, Spain

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1998 in Journal of Controlled Release
Verified
Journal Article
Closed access
MIManoli Igartua
Manoli Igartua
Rosa Maria HernandezRosa Maria Hernandez
Rosa Maria Hernandez
AEA Esquisabel
A Esquisabel
Alicia Rodríguez-GascónAlicia Rodríguez-Gascón
Alicia Rodríguez-Gascón
MCM.B Calvo
M.B Calvo
JPJ.L Pedraz
J.L Pedraz

22 July 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MMM. Moreno-Sastre
M. Moreno-Sastre
MPM. Pastor
M. Pastor
Claudio SalomonClaudio Salomon
Claudio Salomon
AEA. Esquisabel
A. Esquisabel
José Luis PedrazJosé Luis Pedraz
José Luis Pedraz
As the WHO stated, lower respiratory infections are the third leading cause of death. In addition, it is remarkable that antimicrobial resistance represents a huge threat. Thus, new therapeutic weapons are required. Among the possible alternatives, antibiotic encapsulation in nanoparticles has gained much attention in terms of improved tolerability, activity and ability to combat the resistance mechanisms of bacteria. In this regard, this review article focuses on the latest nanocarrier approaches for inhalatory therapy of antibiotics. First, the technology related to lung disposition will be reviewed. Then, nanocarrier systems will be introduced and the challenges required to perform adequate pulmonary deposition analysed. In the following part, drug delivery systems (DDSs) on the market or in clinical trials are described and, finally, new approaches of nanoparticles that have reached pre-clinical stage are enumerated. Altogether, this review aims at gathering together the novel nanosystems for anti-infectious therapy, underlining the potential of DDSs to improve and optimize currently available antibiotic therapies in the context of lung infections.

1 February 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MMMaría Moreno-Sastre
María Moreno-Sastre
MPMarta Pastor
Marta Pastor
AEAmaia Esquisabel
Amaia Esquisabel
ESEulàlia Sans
Eulàlia Sans
MVMiguel Viñas
Miguel Viñas
José Luis PedrazJosé Luis Pedraz
José Luis Pedraz

1 September 2016 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
ESEulalia Sans
Eulalia Sans
EFEster Fusté
Ester Fusté
BMB. Martínez-Garriga
B. Martínez-Garriga
AMA. Merlos
A. Merlos
MPM. Pastor
M. Pastor
Miguel VinasMiguel Vinas
Miguel Vinas

1 December 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MPMarta Pastor
Marta Pastor
MMMaría Moreno-Sastre
María Moreno-Sastre
AEAmaia Esquisabel
Amaia Esquisabel
ESEulàlia Sans
Eulàlia Sans
MVMiguel Viñas
Miguel Viñas
José Luis PedrazJosé Luis Pedraz
José Luis Pedraz

1 January 1997 in Journal of Microencapsulation
Verified
Journal Article
Closed access
PDF file
MIManoli Igartua
Manoli Igartua
Rosa Maria HernandezRosa Maria Hernandez
Rosa Maria Hernandez
AEA. Esquisabel
A. Esquisabel
Alicia Rodríguez-GascónAlicia Rodríguez-Gascón
Alicia Rodríguez-Gascón
MCM. B. Calvo
M. B. Calvo
JPJ. L. Pedraz
J. L. Pedraz
Poly(D, L-lactide-co-glycolide) microspheres containing BSA were prepared by a modified solvent evaporation method using a double emulsion. These microspheres were characterized for size, morphology, surface adsorbed protein, encapsulation efficiency and release kinetics. The influence of two formulation variables (the procedure to obtain the first emulsion and the lyophilization of the microspheres once obtained) on the physical characteristics and release behaviour of the microspheres was also investigated. Sonicated microspheres were smooth and spherical, with a mean particle size of 20 μm and an encapsulation efficiency of 81%. When the first emulsion was prepared by vortex mixing the particles were irregular and porous, with a mean size of 31 μm and a lower encapsulation efficiency (56%). The sonication allows a more homogeneous emulsion as well as a lower percentage of albumin adsorbed on the surface. The in vitro release profile was described as a biexponential process with an initial burst effect due to the release of the protein adsorbed on the microsphere surface and a second sustained release phase due to protein diffusion through the channels or pores formed in the polymer coat. The release of BSA was dependent on the preparation method. The greatest burst release was found for microspheres formulated using the vortex mixer, 58% of the encapsulated protein was released during the first 24 h, whereas sonicated microspheres released 32.2%. This burst effect could be reduced by lyophilizing the micro-spheres following their preparation. The amount of protein released decreased to 28.3% and 51.6% in sonicated and non-sonicated microspheres respectively, when they were lyophilized.